NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Dual Boosted Protease Inhibitor Regimens Without Any Additional Antiretroviral Therapy in HIV-1 Infected Patients (ANRS127)

NCT00122603

CompletedPhase 2

Sponsor: French National Agency for Research on AIDS and Viral Hepatitis

Conditions: HIV Infections

Interventions: Fosamprenavir, Saquinavir

Countries: France

The purpose of this study is to evaluate virological efficacy and safety of two double protease inhibitor regimens: atazanavir/fosamprenavir/ritonavir 300 mg once daily/ 700/100 mg twice daily, versus atazanavir/saquinavir/ritonavir 300/1500/100 mg once daily in protease inhibitor naive HIV-1 patients.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Protease inhibitor naive patients
* Wild type genotype
* CD4 greater than 200/mm3
* Viral load between 10,000 copies/ml and 750,000 copies/ml
* Signed informed consent

Exclusion Criteria:

* Pregnancy; breast feeding
* Antiretroviral (ARV) pretreated patients
* Hyperlipidemic treatment
* Evolutive disease

Locations (1)

Paris, France